Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Company Overview

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.16 to $0.39
• 52-Week Range: N/A
• Volume: 1.27 million shs
• Average Volume: 160,047 shs
• Market Capitalization: $10.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.50
• Consensus Rating: Buy

MDNA Stock Analysis - Frequently Asked Questions

How were Medicenna Therapeutics' earnings last quarter?

Medicenna Therapeutics Corp. (NASDAQ:MDNA) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03.

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), e.l.f. Beauty (ELF), Meta Platforms (META), Arista Networks (ANET) and AppLovin (APP).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 8/29/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MDNA
• CIK: 1807983
• Web: www.medicenna.com
• Phone: (416) 648-5555
• Fax: 416-572-7501
• Employees: 16
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Medicenna Therapeutics: $2.50
• High Price Target: $2.50
• Low Price Target: $2.50
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -42.68%
• Return on Assets: -35.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.57
• Quick Ratio: 9.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.32 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 69,637,000
• Free Float: 46,587,000
• Market Cap: $10.93 million
• Optionable: Not Optionable
• Beta: 1.30